Understanding how immune enzymes acquired their precise biochemical identities matters because those identities determine which metabolic pathways they control — and which diseases they influence. IL4I1, an enzyme increasingly recognized as a checkpoint-like immunosuppressor in cancer and autoimmunity, selectively oxidizes aromatic amino acids like phenylalanine and tryptophan. Pinpointing exactly how and when it gained that selectivity, versus its evolutionary relatives with far broader substrate ranges, could open new routes for therapeutic targeting.
Researchers publishing in PNAS combined ancestral sequence reconstruction with biochemical characterization to trace how human IL4I1 diverged from a broad-specificity L-amino acid oxidase (LAAO) ancestor. By synthesizing and testing ancient enzyme variants, they identified the specific evolutionary transitions that narrowed substrate preference toward aromatic amino acids. The analysis showed that modern IL4I1's selectivity is not simply a loss of function but a derived, actively shaped biochemical identity that distinguishes it from snake venom LAAOs and other LAAO family members that retain wide substrate promiscuity.
This work sits at a productive intersection of evolutionary biochemistry and immunology. IL4I1 has attracted considerable attention over the past decade as a tumor microenvironment immunosuppressor: it depletes phenylalanine locally and generates metabolites that inhibit T-cell activity, reminiscent of IDO1/TDO2-mediated tryptophan catabolism. Understanding its substrate specificity at a mechanistic, evolutionary level strengthens the rationale for designing selective inhibitors that would spare related enzymes. The limitation here is that ancestral reconstruction, while increasingly powerful, involves computational inference — resurrected ancestral sequences are models, not historical facts, and different reconstruction algorithms can yield different biochemical conclusions. This is a mechanistic, non-clinical study with no human or animal disease model, placing it firmly in the foundational science tier. Still, for researchers developing next-generation immunometabolic therapies, the structural logic uncovered here is genuinely useful — incrementally but meaningfully advancing the field.